GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Retained Earnings

Virax Biolabs Group (Virax Biolabs Group) Retained Earnings : $-14.80 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Virax Biolabs Group's retained earnings for the quarter that ended in Sep. 2023 was $-14.80 Mil.

Virax Biolabs Group's quarterly retained earnings declined from Sep. 2022 ($-7.78 Mil) to Mar. 2023 ($-11.79 Mil) and declined from Mar. 2023 ($-11.79 Mil) to Sep. 2023 ($-14.80 Mil).

Virax Biolabs Group's annual retained earnings declined from Mar. 2021 ($-4.63 Mil) to Mar. 2022 ($-6.34 Mil) and declined from Mar. 2022 ($-6.34 Mil) to Mar. 2023 ($-11.79 Mil).


Virax Biolabs Group Retained Earnings Historical Data

The historical data trend for Virax Biolabs Group's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Retained Earnings Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Retained Earnings
-3.98 -4.63 -6.34 -11.79

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Retained Earnings Get a 7-Day Free Trial -5.18 -6.34 -7.78 -11.79 -14.80

Virax Biolabs Group Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Virax Biolabs Group  (NAS:VRAX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Virax Biolabs Group (Virax Biolabs Group) Business Description

Traded in Other Exchanges
N/A
Address
20 North Audley Street, London, GBR, W1K 6LX
Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.